What is William Blair's Forecast for ALLO Q1 Earnings?

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Allogene Therapeutics in a research note issued to investors on Friday, March 14th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.29) for the quarter. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics' Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.30) EPS.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06.

ALLO has been the topic of several other reports. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday. Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday. Finally, Citizens Jmp upgraded Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a report on Friday. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Allogene Therapeutics has an average rating of "Moderate Buy" and an average target price of $9.40.

Remove Ads

Allogene Therapeutics Stock Down 4.6 %

Shares of ALLO traded down $0.09 during mid-day trading on Monday, reaching $1.85. The company's stock had a trading volume of 3,372,618 shares, compared to its average volume of 3,035,002. The business has a fifty day moving average of $1.94 and a 200 day moving average of $2.31. The company has a market cap of $387.89 million, a price-to-earnings ratio of -1.19 and a beta of 1.02. Allogene Therapeutics has a 1 year low of $1.32 and a 1 year high of $4.74.

Institutional Investors Weigh In On Allogene Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ALLO. Cibc World Markets Corp bought a new stake in Allogene Therapeutics during the fourth quarter worth about $26,000. PAX Financial Group LLC bought a new stake in Allogene Therapeutics during the 4th quarter worth approximately $27,000. RPO LLC acquired a new stake in Allogene Therapeutics during the 4th quarter valued at $31,000. Caption Management LLC bought a new position in Allogene Therapeutics in the 4th quarter valued at $32,000. Finally, Syon Capital LLC acquired a new position in Allogene Therapeutics in the fourth quarter worth $39,000. Institutional investors and hedge funds own 83.63% of the company's stock.

Insider Activity

In related news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the transaction, the insider now owns 250,713 shares of the company's stock, valued at $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the sale, the executive vice president now directly owns 488,054 shares in the company, valued at $868,736.12. The trade was a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,710 shares of company stock valued at $92,125. 24.30% of the stock is owned by company insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).